The exciting results of the recent Phase 2A proof-of-concept clinical trial on NLX-112, a new drug candidate for the treatment of Parkinson's disease are discussed in a new interview between Arthur Roach, director of Parkinson's UK Virtual Biotech, and Adrian Newman-Tancredi, CEO of Neurolixis. NLX-112 is a first-in-kind non-dopaminergic drug for treatment of dyskinesia and other symptoms of Parkinson's disease and exhibited positive effects against dyskinesia and parkinsonism in a recent study supported by The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK research foundations. Neurolixis is proud to have joined forces with these leading research foundations. Parkinson's disease affects 9 million people worldwide and is the second most common neurodegenerative disease after Alzheimer's. 

See the interview on YouTube.